Table 4 Univariate Analysis of DFS in Patients with EGFR Active Mutations.

From: Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

Genes

Category

N = 43

5-year DFS (%)

Univariate Analysis

HR (95% CI)

p-value

CDKN2B

WT

27

51.6

  

MUT

16

7.1

5.618 (1.995–15.827)

0.001

CDKN2A

WT

33

54.7

  

MUT

10

14.6

1.887 (0.728–4.892)

0.191

CDKN1B

WT

34

28.7

  

MUT

9

62.2

0.435 (0.123–1.540)

0.197

TP53

WT

31

47.0

  

MUT

12

31.3

2.495 (0.956–6.510)

0.062

STK11

WT

36

44.7

  

MUT

7

33.3

0.864 (0.246–3.035)

0.820

RB1

WT

36

41.1

  

MUT

7

28.6

1.875 (0.601–5.848)

0.279

ARID1A

WT

35

24.1

  

MUT

8

100

0.136 (0.030–2.492)

0.056

FBXW7

WT

37

30.3

  

MUT

6

62.5

0.715 (0.196–2.621)

0.613

EGFR*

WT

37

36.5

  

MUT

6

44.4

1.737 (0.566–5.329)

0.334

  1. Note: Only genes mutated in more than six patients were analyzed. *Refers to EGFR non-active mutations, i.e., excluding Exon19 deletion and L858R. DFS, disease-free survival; N, number; HR, hazard ratio; CI, confidence interval; PY, pack-year; WT, wild type; MUT, mutated; Bold values are those with statistical significance of p < 0.05.
Back to article page